Selective vasopressin type 2 receptor antagonist for patients with cirrhosis

To assess the benefits and harms of selective vasopressin type 2 receptor antagonist drugs for patients with cirrhosis and ascites.

This is a protocol.

Published:

7 December 2011

Authors:

Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Mendez-Sanchez N, Uribe M

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Mendez-Sanchez N, Uribe M. Selective vasopressin type 2 receptor antagonist for patients with cirrhosis. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD009523. DOI: 10.1002/14651858.CD009523